Invitae Corporation (NVTA)
0.02
-0.01 (-32.20%)
At close: Feb 14, 2024, 8:59 PM
Company Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally.
The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services.
It serves patients, healthcare providers, biopharma companies, and other partners.
The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012.
Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
Invitae Corporation
| Country | United States |
| IPO Date | Feb 12, 2015 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 1,700 |
| CEO | Kenneth D. Knight |
Contact Details
Address: 1400 16th Street San Francisco, California United States | |
| Website | https://www.invitae.com |
Stock Details
| Ticker Symbol | NVTA |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001501134 |
| CUSIP Number | 46185L103 |
| ISIN Number | US46185L1035 |
| Employer ID | 27-1701898 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Kenneth D. Knight | President, Chief Executive Officer & Director |
| Ana J. Schrank | Chief Accounting Officer & Chief Financial Officer |
| Dr. David B. Sholehvar M.D. | Chief Operating Officer |
| Desarie French | Chief Talent Officer |
| Dr. Randal W. Scott Ph.D. | Co-Founder & Chairman of the Board |
| Dr. W. Michael Korn M.D. | Chief Medical Officer |
| Hoki Luk | Head of Investor Relations and Capital Markets |
| Robert Guigley | Chief Commercial Officer |
| Shelly D. Guyer | Chief Sustainability Officer |
| Thomas R. Brida | General Counsel, Chief Compliance Officer & Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Aug 08, 2024 | 8-K | Current Report |
| Jul 31, 2024 | 8-K | Current Report |
| Jul 01, 2024 | 8-K | Current Report |
| Jun 04, 2024 | 8-K | Current Report |
| May 02, 2024 | 8-K | Current Report |
| Apr 04, 2024 | 8-K | Current Report |
| Mar 06, 2024 | 8-K | Current Report |
| Feb 21, 2024 | 25-NSE | Filing |
| Feb 14, 2024 | 8-K | Current Report |